Evaluation and management of acute high-grade immunotherapy-related neurotoxicity

Sandoval, Marcelo; Wechsler, Adriana H.; Alhajji, Zahra; Viets-Upchurch, Jayne; Brock, Patricia; Lipe, Demis N.; Al-Buraiki, Aisha; Yeung, Sai Ching Jim

doi:10.1016/j.heliyon.2023.e13725

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 172 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GBS is a group of autoimmune disorders manifested by acute polyradiculoneuropathy, and it is the most common cause of acute flaccid paralysis [ 6 ]. ICI-associated GBS is seen in 0.1%-0.3% of all patients receiving ICIs [ 19 ]. It has mostly been observed with the combination therapy of ipilimumab and nivolumab [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

Immune Checkpoint Inhibitor-Induced Guillain Barre Syndrome: A Single-Institution Case Report and Narrative Review

Idogun,

Hafez-Khayyata,

Ezekwudo

2024

Cureus

View full text Add to dashboard Cite

Guillain-Barré syndrome (GBS) resulting from the use of immune checkpoint inhibitors (ICIs) is relatively uncommon but has been reported. Herein, we discuss a case of a 67-year-old patient who received neoadjuvant ICI for treatment of non-small cell lung cancer and then presented with lower extremity weakness and areflexia, progressing to respiratory muscle and upper extremity weakness. Given the increasing use of ICI in cancer management, awareness of neurological autoimmune side effects is essential. ICI-mediated GBS can be severe and fatal if not diagnosed promptly. We discuss a case of ICI-induced GBS and review literature on current management approaches.

show abstract

Section: Discussionmentioning

confidence: 99%